Active Ingredient History
Donepezil, marketed under the trade name Aricept, is a medication used in the palliative treatment of Alzheimer's disease. Aricept is indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild to moderate Alzheimer’s Disease, as well as in patients with severe Alzheimer’s Disease. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. Donepezil has been tested in other cognitive disorders including Lewy body dementia and Vascular dementia, but it is not currently approved for these indications. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adult (Phase 1)
Aged (Phase 4)
Alcoholism (Phase 2/Phase 3)
Allergy and Immunology (Phase 1)
Amblyopia (Phase 4)
Anxiety Disorders (Phase 3)
Aphasia (Phase 4)
Arthritis, Rheumatoid (Phase 3)
Arthroplasty, Replacement, Knee (Phase 4)
Attention (Early Phase 1)
Autism Spectrum Disorder (Phase 2)
Autistic Disorder (Phase 4)
Bipolar Disorder (Phase 4)
Brain Injuries (Phase 1/Phase 2)
Brain Injuries, Traumatic (Phase 3)
Brain Ischemia (Phase 2)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 2)
Central Nervous System Diseases (Phase 1)
Choline (Early Phase 1)
Cholinesterase Inhibitors (Phase 4)
Cocaine-Related Disorders (Phase 2)
Cognition (Phase 1)
Cognition Disorders (Phase 4)
Cognitive Dysfunction (Phase 4)
Coronary Vasospasm (Phase 2)
Deficiency Diseases (Phase 2)
Delirium (Phase 4)
Dementia ()
Dementia, Vascular (Phase 4)
Depression (Phase 4)
Dermatology (Phase 1)
Diabetes Mellitus, Type 2 (Phase 2)
Down Syndrome (Phase 3)
Electronic Data Processing (Early Phase 1)
Fatigue (Phase 2)
Femur (Phase 3)
Fractures, Bone (Phase 4)
Fragile X Syndrome (Phase 2)
Geriatrics (Phase 4)
Healthy Volunteers (Phase 1)
Hearing Loss, Sensorineural (Early Phase 1)
Irritants (Phase 2)
Ischemic Stroke (Phase 3)
Kidney Failure, Chronic (Phase 4)
Lewy Body Disease (Phase 4)
Lung Neoplasms (Phase 3)
Mania (Phase 4)
Memory (Phase 4)
Memory Disorders (Phase 4)
Mental Health (Phase 4)
Migraine Disorders (Phase 2)
Multiple Sclerosis (Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 4)
Musculoskeletal Diseases (Phase 4)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Neuralgia (Phase 4)
Neurocognitive Disorders (Phase 4)
Osteoarthritis (Phase 3)
Osteoporosis (Phase 2)
Pain (Phase 2)
Palliative Care (Phase 2)
Parkinson Disease (Phase 4)
Postoperative Complications (Phase 4)
Psychophysiologic Disorders (Phase 3)
Psychotic Disorders (Phase 4)
Radiation Injuries (Phase 2)
Rett Syndrome (Phase 3)
Schizophrenia (Phase 4)
Sleep Apnea, Obstructive (Phase 4)
Sleep Deprivation (Phase 4)
Sleepiness (Phase 4)
Sleep Wake Disorders (Phase 2)
Smoking (Phase 2)
Spine (Phase 4)
Stroke (Phase 4)
Subarachnoid Hemorrhage (Phase 2)
Supranuclear Palsy, Progressive (Phase 2)
Urinary Retention (Early Phase 1)
Visual Perception (Early Phase 1)
Wound Healing (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
